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Abstract
Background:  Hepatotoxicity is one of the most serious complications of highly active
antiretroviral therapy (HAART). The aim of this report is to analyse an HIV infected patient on
HAART including nevirapine and taking antidepressive agents, with acute toxic hepatitis.
Case presentation: A 39 year old patient diagnosed as HIV positive one month ago administered
to the clinical ward of the Department of Infectious Diseases and Clinical Microbiology in Ege
University Medical School with high fever, malaise, nausea, diarrheae and elevated liver enzymes
(ALT 1558 U/L, AST 4288 U/L). He has been using HAART including zidovudine+lamivudine (2 
1/day) and nevirapine (2  200 mg/day, following dose escalation) for 22 days, sertralin and
diazepam for 12 days and lithium for 10 days.
The patient was hospitalized. Antiretroviral and antidepressant treatments were stopped. The day
after admission, his fever dropped and his symptoms improved. Clinical improvement continued on
the following days. The patient was discharged upon his request on the 14th day of hospitalization.
The liver function tests returned to normal levels in two weeks following discharge.
Conclusion: Close monitoring of liver enzymes during the first 12 weeks of nevirapine therapy is
critical to prevent life threatening events.
Background
Hepatotoxicity is one of the most serious complications of
highly active antiretroviral therapy (HAART). While hepa-
totoxicity was described for all antiretroviral classes, riton-
avir was attributed the highest risk among all drugs [1,2].
Nevirapine (NVP) is a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) frequently used in HAART
regimens. The most common adverse event encountered
during NVP use is cutaneous rash. Recently severe hepatic
reactions attributed to NVP administered as part of
HAART or in post-exposure prophylaxis (PEP) regimens,
have also been reported [3–6].
In this report, we present an HIV infected patient on
HAART including nevirapine and taking antidepressive
agents, with acute toxic hepatitis.
Case presentation
A 39 year old HIV positive patient on HAART followed up
by the authors, administered to the clinical ward of the
Department of Infectious Diseases and Clinical Microbi-
ology in Ege University Medical School with high fever,
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malaise, nausea and severe diarrheae. He had adminis-
tered to the State Hospital the day before and was trans-
ferred to our hospital upon the detection of highly
elevated liver enzymes (ALT 1558 U/L, AST 4288 U/L).
The patient was diagnosed as HIV positive one month ago
and has been using HAART including zidovudine+lami-
vudine (2  1/day) and nevirapine (2  200 mg/day, fol-
lowing dose escalation) for 22 days. He was also under
psychiatric control due to severe depression and has been
using sertralin and diazepam for 12 days and lithium for
10 days. His baseline plasma viral RNA was >75.000 cop-
ies/mL, baseline CD4+ T cell count 277/mm3, and liver
function tests were normal. He had been asked to refer to
the hospital weekly during the first month of HAART for
routine tests; but he did not return to the hospital for
these routine controls.
Physical findings revealed low-grade fever (37.6C), phar-
yngial hyperemia and seborrhoeik dermatitis on both
cheeks. Routine laboratory test results on admission were
as follows: hemoglobin 13.8 g/dL; white blood cell count
4.3   103/mm3 with 58.6% neutrophiles, 22.5% lym-
phocytes, 6.5% monocytes, and 12.4% eosinophils; plate-
lets 2.4  107/mm3, erythrocyte sedimentation rate 42
mm/hr, blood urea nitrogen 83 mg/dL, serum creatinine
2.36 mg/dL, AST 2221 U/L, ALT 377 U/L, ALP 577 U/L,
GGT 246 U/L, total bilirubine 1.70 mg/dL, direct biliru-
bine 1.57 mg/dL.
The patient was hospitalized. Antiretroviral and antide-
pressant treatments were stopped. Since the oral intake of
the patient was low, infusion of balanced electrolyte solu-
tions were started. Blood, pharyngial, stool and urine cul-
tures were performed and all were negative for any
pathogens. Cryptosporidium and Blastocystis hominis cysts
were identified in the examination of direct and stained
stool specimens. The patient was immune to hepatitis A,
vaccinated and anti-HBs positive for hepatitis B, and had
no serological markers for hepatitis C. IgG antibodies
were positive for CMV and EBV viral capsid antigen. His
anti-toxoplasma IgM and IgG antibodies were negative.
Abdominal ultrasonographic findings and the radiologic
examination of the lungs were normal. His viral load has
decreased to 525 copies/mL at the end of 22 days of
antiretroviral treatment.
The day after admission, his fever dropped and his symp-
toms improved. Azithromycin 1 g/day was administered
for cryptosporidiasis on the second day of hospitalization.
Clinical improvement continued on the following days.
No rise in fever was observed until the day of discharge.
Diarrhea stopped on the sixth day of hospitalization. Liver
function tests were controlled every two days. Lower levels
were obtained in each test. No other medication was start-
ed while he was hospitalized.
The patient was discharged upon his request on the 14th
day of hospitalization. His liver function test results on
the 14th day were as follows: AST 61 U/L, ALT 156 U/L,
ALP 379 U/L, GGT 138 U/L, total bilirubine 1.1 mg/dL,
and direct bilirubine 0.75 mg/dL.
He was called for control visits every week. The liver func-
tion tests returned to normal levels in two weeks. Azithro-
mycin treatment was stopped at the end of one month.
Antiretroviral treatment could not be restarted immedi-
ately after total recovery due to the financial problems of
the patient. Zidovudine+lamivudine (2  1/day) and indi-
navir (3  800 mg) were administered three months after
the discontinuation of HAART. Antidepressant treatment
was restarted with paroxetine one month after discharge.
Following four weeks of antiretroviral treatment, all rou-
tine tests of the patient were normal, plasma viral RNA
1950 copies/mL and CD4+ T cell count 579/mm3.
Hepatotoxicity is a major side effect of antiretroviral
drugs, limiting their use in treatment regimens and in
combination with other hepatotoxic drugs. Up to date,
hepatic toxicity has been described for all antiretroviral
groups [1,2,7]. While the risk of severe hepatotoxicity was
indicated to be 5-fold higher for patients taking ritonavir
in one study [2], high rate of hepatotoxicity irrespective of
drug class was reported in another [1]. Among the
NNRTI's NVP or efavirenz (EFV) were significantly more
likely to be associated with Grade 3/4 hepatotoxicity [1].
Although NVP toxicity seems to be related to several fac-
tors such as the baseline CD4+ T cell count, baseline ALT
and AST levels and coinfection with hepatitis B or C, pa-
tients lacking these risk factors may also be prone to the
hepatic side effects of the drug [2,6,8,9].
Although not very frequent, antidepressive agents have
also been accused of having hepatotoxic side effects
[10,11]. Most of these reactions are indicated to be unpre-
dictable and dose-independent [10]. While there are re-
ports on some neuroleptic and psychotropic drugs that
should not be used with various antiretrovirals, there is no
warning limiting the use of NVP with antidepressants
[12]. The fact that the patient presented above has been
using three antidepressant drugs together with antiretrovi-
rals complicates the situation. Although studies have
clearly demonstrated a hepatotoxic potential for the
above stated compounds, it is hard to differentiate which
drug is responsible for the adverse event in this case. A
possible explanation would be that the combined hepato-
toxic effect of antidepressants with NVP have precipitated
the hepatic event. The finding that none of the factors con-
sidered to be related to the hepatotoxicity of NVP wereAnnals of Clinical Microbiology and Antimicrobials 2002, 1 http://www.ann-clinmicrob.com/content/1/1/1
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present in the patient was also an interesting point to be
considered.
Most reports on the hepatotoxicity of NVP indicate that
clinical hepatitis is not common and the abnormality in
liver function tests are reversible after the discontinuation
of the drug [3,5,9]. However, there are other reports de-
scribing icteric hepatitis cases which are also reversible,
due to NVP [8] and although rare, reports on cases who
developed fulminant hepatitis with consequent liver fail-
ure either requiring transplantation or being fatal [4]. Due
to the high rate of discontinuation, mortality of hepato-
toxic events due to NVP is low [1]. As indicated above, the
patient presented also recovered totally after the discon-
tinuation of antidepressant and antiretroviral treatment.
Since the antidepressant treatment of the patient had to be
continued, a new antiretroviral regimen which did not in-
clude NVP was administered to the patient after recovery.
Besides, the former antidepressants were replaced with
paroxetine due to its low rate of hepatotoxicity. The pa-
tient is still closely monitored. He is clinically well and
has no abnormal laboratory findings.
Conclusions
The rapidly increasing number of reports on the hepato-
toxicity of NVP has drawn the attention to its use in
HAART and PEP. NVP has not been recommended for
PEP use and should not be included in the regimen due to
its serious adverse effects. However it is a good alternative
drug in HAART regimens and its hepatotoxic potential
should not limit its use in antiretroviral treatment regi-
mens. Close monitoring of liver enzymes during the first
12 weeks of therapy is critical to prevent life threatening
events. Discontinuation of the drug permanently may aid
in reducing mortality.
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